Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients.

Trial Profile

Clot regression effects of rivaroxaban in treatment of venous thromboembolism in cancer patients.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top